Micro Emerging Active

HarbourVest initiates position in Generate Biomedicines

New narrative with limited coverage — still forming.

Score
0.2
Velocity
▲ 0.0
Articles
2
Sources
2

Sentiment Timeline

Event Timeline

Jun 25, 2026
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) Bullish
May 31, 2026
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer Neutral

Timeline

Last UpdatedMay 31, 2026